Phase I study of AZD9592 in solid tumors

Phase 1

Recruiting

• Conditions: Recurrent or metastatic Head and NeckSquamous Cell Carcinoma of the oral cavity,oropharynx, hypopharynx or larynx, Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer; MedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104; MedDRA version: 20.0Level: LLTClassification code: 10001160Term: Adenocarcinoma lung Class: 10029104; MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864; MedDRA version: 21.0Level: PTClassification code: 10052358Term: Colorectal cancer metastatic Class: 100000004864; MedDRA version: 21.0Level: PTClassification code: 10060121Term: Squamous cell carcinoma of head and neck Class: 100000004864; MedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non-small cell lung cancer NOS Class: 10029104; MedDRA version: 21.0Level: PTClassification code: 10041826Term: Squamous cell carcinoma of lung Class: 100000004864; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2022-501570-18-00
• Lead Sponsor: Astrazeneca AB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-28
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 626

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):